BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36181299)

  • 1. NEIL3 promotes hepatoma epithelial-mesenchymal transition by activating the BRAF/MEK/ERK/TWIST signaling pathway.
    Lai HH; Hung LY; Yen CJ; Hung HC; Chen RY; Ku YC; Lo HT; Tsai HW; Lee YP; Yang TH; Chen YY; Huang YS; Huang W
    J Pathol; 2022 Dec; 258(4):339-352. PubMed ID: 36181299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway.
    Hou CH; Lin FL; Hou SM; Liu JF
    Mol Cancer; 2014 Oct; 13():236. PubMed ID: 25326651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CASC15 promotes epithelial to mesenchymal transition and facilitates malignancy of hepatocellular carcinoma cells by increasing TWIST1 gene expression via miR-33a-5p sponging.
    Li Y; Chen G; Yan Y; Fan Q
    Eur J Pharmacol; 2019 Oct; 860():172589. PubMed ID: 31401158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
    Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1.
    Lee S; Kang E; Lee U; Cho S
    BMC Cancer; 2023 Jul; 23(1):703. PubMed ID: 37495969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
    Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
    J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of microRNA-140-3p inhibits epithelial-mesenchymal transition, invasion, and metastasis of hepatocellular carcinoma through inactivation of the MAPK signaling pathway by targeting GRN.
    Zhang QY; Men CJ; Ding XW
    J Cell Biochem; 2019 Sep; 120(9):14885-14898. PubMed ID: 31044454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
    Zhang C; Guo F; Xu G; Ma J; Shao F
    Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.
    Wang CH; Guo ZY; Chen ZT; Zhi XT; Li DK; Dong ZR; Chen ZQ; Hu SY; Li T
    Sci Rep; 2015 Jul; 5():12366. PubMed ID: 26190376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
    Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
    J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of hepatic stimulator substance expression promotes hepatocellular carcinoma metastasis partly through ERK-activated epithelial-mesenchymal transition.
    Jia XW; Li ZW; Dong LY; Sun GY; Wang X; Gao J; Li YP; Wu Y; An W
    Lab Invest; 2018 Jul; 98(7):871-882. PubMed ID: 29497174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA
    Tong Y; Wang M; Dai Y; Bao D; Zhang J; Pan H
    Hum Gene Ther Clin Dev; 2019 Sep; 30(3):129-141. PubMed ID: 30963785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of IQGAP3 in metastasis and epithelial-mesenchymal transition in human hepatocellular carcinoma.
    Shi Y; Qin N; Zhou Q; Chen Y; Huang S; Chen B; Shen G; Jia H
    J Transl Med; 2017 Aug; 15(1):176. PubMed ID: 28810875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.
    Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Su C; Chen J
    Cancer Lett; 2013 Sep; 337(2):226-36. PubMed ID: 23684551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells.
    Guo J; Lan Z
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):37-45. PubMed ID: 31852247
    [No Abstract]   [Full Text] [Related]  

  • 20. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
    Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
    Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.